 SHELTON, CT ACCESSWIRE July 13, 2020 NanoViricides, Inc. NYSE American: NNVC the Company a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, today announced that it has completed an underwritten public offering the Offering with gross proceeds of 11.5 million before deducting underwriting discounts and other estimated offering expenses. The Offering included 1,369,863 shares and a fully exercised Underwriters over-allotment option of 205,479 additional shares of the Companys common stock at the public offering price of 7.30 per share. The Offering closed on Friday, July 10, 2020. 